News
Author: admin als-handoff
-
Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC
June 13, 2017. Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017. MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, June 13, 2017 /CNW/ — Achieve Life Sciences, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (OncoGenex) today announced that the Registration Statement on Form S-4 has been…
-
Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference (“SRNT”)
March 8, 2017. Professor Nancy Rigotti, MD, will chair a symposium entitled “Cytisine Update: Moving Research Forward Toward a Globally Affordable Tobacco Cessation Medication” Other presenters include Natalie Walker, PhD; David Shurtleff, PhD; SooHee Jeong, PhD; and Kamran Siddiqi, PhD. MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, March. 8, 2017 /PRNewswire/ — Achieve…
-
Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National Institutes of Health to Advance the Development of Cytisine for Smoking Cessation
March 1, 2017. Ongoing IND-enabling Non-clinical Program to Support the Use of Cytisine in Smoking Cessation. Multiple Key Cytisine Development and Regulatory Milestones Expected in 2017. MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, March 1, 2017 /CNW/ — Achieve Life Science, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (OncoGenex) today announced a…
-
OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
March 8, 2017. Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation. Multiple Clinical and Regulatory Milestones Expected in the Next 12-18 Months. BOTHELL, Wash. and VANCOUVER, British Columbia and MILL VALLEY, Calif., Jan. 5, 2017 /CNW/ –OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (“OncoGenex”), a publicly held…